MaxCyte Minutes Newsletter – Q3 2022
CRISPR Electroporation of T Cells Improves Treatment in Patients with Refractory Cancer
At MaxCyte®, we know that cells are precious. Especially when they are the key to novel treatments for patients in need. In this issue of the MaxCyte Minutes newsletter, we share some featured news, events, and technical content to show how we can help you with your next cell engineering project and expedite your research from concept to clinic and commercialization.
IN THE NEWS
MaxCyte to support LG Chem CAR T programs
MaxCyte is thrilled to announce that we are partnering with LG Chem to support their CAR T programs for solid tumors. This partnership represents our first strategic platform license (SPL) with a South Korean company and broadens our reach into Asia. This collaboration enables us to provide advanced technologies that support the clinical and commercial development of engineered cell therapies that can treat cancer patients across the globe.
Exploring Flow Electroporation® for Cell Engineering
Our Chief Scientific Officer, Dr. Cenk Sumen, recently spoke with Technology Networks about the numerous applications of cell engineering and how Flow Electroporation® technology can support cell engineering from small- to large-scale.
CELL & GENE THERAPY
Upcoming Webinar. Beyond affinity: antibody discovery, optimization, and developability screening from mammalian display libraries
Join us for a Lab roots Webinar and learn about detecting and avoiding antibodies with problematic developability profiles during early discovery. You can also find out about IONTAS’ novel technology for displaying antibodies on the surface of mammalian cells for antibody screening.
Date: Wednesday, October 19, 2022
Time:: 6:00am (PDT), 8:00am (EDT), 9:00am (CEST) REGISTER NOW 
Featured Presentation: Which industry partner should I collaborate with? A scientists’ journey to implementing an innovative technology
At this year’s ASGCT (American Society of Gene and Cell Therapy) annual meeting, we were honored to have two of our clients, Dr. Jonathan Yen and Dr. Alicja Copik, present. They discussed how MaxCyte helped them unlock the full potential of their research by solving development and commercialization challenges.
Poster: In Vitro Characterization of CD19 CAR T Cells Derived
We also presented a poster at ASGCT! Here, MaxCyte electroporation was used to engineer T cells with mRNA. CAR T cells efficiently targeted and killed CD19-expressing cancer cells. If you missed the poster presentation, it’s available to download on our website.
BIOPROCESSING
Transient Protein Expression Will Revolutionize Bioproduction
Our Chief Scientific Officer, Dr. Cenk Sumen, recently contributed to a Genetic Engineering & Biotechnology News article offering insights into transient protein expression and its ability to transform bioproduction.
FOCUS ON
Rick Urbanski, Manufacturing Engineer
For this issue, we spent time with Rick Urbanski, from the Manufacturing Engineering team at MaxCyte. He designs and builds tooling to support manufacturing operations throughout the MaxCyte product portfolio. Let’s meet Rick!
MEET US
September 17, 2022; 6:00 pm – 10:00 pm
Valley Forge Casino Resort King of Prussia, PA
Emily Whitehead Foundation – Believe Ball
VIEW ALL EVENTS 
September 27 – September 30
Boston, MA
